-+ 0.00%
-+ 0.00%
-+ 0.00%

Scholar Rock Outlines 2026 Strategy Focused on Apitegromab Regulatory Approvals and Commercialization, Leadership Expansion, Commercial Organization Build-Out, and Advancement of Anti-Myostatin Pipeline

Reuters·01/12/2026 12:01:08

Please log in to view news